Corona Remedies’ Rs 655-crore offer-for-sale IPO saw strong demand across investor categories, with overall subscription at 144.54 times and a 28% grey market premium. Given robust institutional interest, the issue is likely to list above its Rs 1,062 price band, though final listing gains will depend on market sentiment on the listing day.